Documents
Application Sponsors
NDA 208464 | GILEAD SCIENCES INC | |
Marketing Status
Application Products
001 | TABLET;ORAL | EQ 25MG BASE | 1 | VEMLIDY | TENOFOVIR ALAFENAMIDE FUMARATE |
FDA Submissions
TYPE 5; Type 5 - New Formulation or New Manufacturer | ORIG | 1 | AP | 2016-11-10 | STANDARD |
EFFICACY; Efficacy | SUPPL | 4 | AP | 2018-07-03 | STANDARD |
EFFICACY; Efficacy | SUPPL | 7 | AP | 2019-02-04 | STANDARD |
EFFICACY; Efficacy | SUPPL | 8 | AP | 2020-02-04 | STANDARD |
EFFICACY; Efficacy | SUPPL | 10 | AP | 2020-08-18 | STANDARD |
EFFICACY; Efficacy | SUPPL | 11 | AP | 2020-08-18 | STANDARD |
LABELING; Labeling | SUPPL | 12 | AP | 2021-03-04 | STANDARD |
LABELING; Labeling | SUPPL | 13 | AP | 2021-09-15 | STANDARD |
EFFICACY; Efficacy | SUPPL | 14 | AP | 2022-10-17 | PRIORITY |
Submissions Property Types
ORIG | 1 | Null | 40 |
SUPPL | 4 | Null | 7 |
SUPPL | 7 | Null | 15 |
SUPPL | 8 | Null | 6 |
SUPPL | 10 | Null | 31 |
SUPPL | 11 | Null | 6 |
SUPPL | 12 | Null | 6 |
SUPPL | 13 | Null | 6 |
SUPPL | 14 | Null | 6 |
CDER Filings
GILEAD SCIENCES INC
cder:Array
(
[0] => Array
(
[ApplNo] => 208464
[companyName] => GILEAD SCIENCES INC
[docInserts] => ["",""]
[products] => [{"drugName":"VEMLIDY","activeIngredients":"TENOFOVIR ALAFENAMIDE FUMARATE","strength":"EQ 25MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"08\/18\/2020","submission":"SUPPL-11","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"}]","notes":""},{"actionDate":"08\/18\/2020","submission":"SUPPL-10","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"}]","notes":""},{"actionDate":"02\/04\/2020","submission":"SUPPL-8","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s008lbl.pdf\"}]","notes":""},{"actionDate":"02\/04\/2019","submission":"SUPPL-7","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208464s007lbl.pdf\"}]","notes":""},{"actionDate":"04\/07\/2017","submission":"SUPPL-1","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208464s001lbl.pdf\"}]","notes":""},{"actionDate":"11\/10\/2016","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/208464s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"11\/10\/2016","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2016\\\/208464s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2016\\\/208464Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2016\\\/208464Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] => [{"actionDate":"08\/18\/2020","submission":"SUPPL-11","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s010,s011ltr.pdf\"}]","notes":">"},{"actionDate":"08\/18\/2020","submission":"SUPPL-10","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s010s011lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s010,s011ltr.pdf\"}]","notes":">"},{"actionDate":"02\/04\/2020","submission":"SUPPL-8","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/208464s008lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/208464Orig1s008ltr.pdf\"}]","notes":">"},{"actionDate":"02\/04\/2019","submission":"SUPPL-7","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/208464s007lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/208464Orig1s007ltr.pdf\"}]","notes":">"},{"actionDate":"07\/03\/2018","submission":"SUPPL-4","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2018\\\/208464Orig1s004ltr.pdf\"}]","notes":"> Label is not available on this site."},{"actionDate":"04\/07\/2017","submission":"SUPPL-1","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/208464s001lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2017\\\/208464Orig1s001ltr.pdf\"}]","notes":">"}]
[actionDate] => 2020-08-18
)
)